Literature DB >> 30323049

Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.

Mojgan Sabet1, Ziad Tarazi1, David C Griffith2.   

Abstract

We have evaluated the activity of meropenem-vaborbactam against clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii in a neutropenic mouse thigh infection model. Data show that meropenem-vaborbactam regimens equivalent to 3-h infusions every 8 h with 2 g meropenem and 2 g vaborbactam produced bacterial killing against strains with MICs of 2 to 16 mg/liter and suggests that this combination may have utility in the treatment of infections caused by P. aeruginosa and A. baumannii.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  A. baumanniizzm321990; P. aeruginosazzm321990; meropenem-vaborbactam

Mesh：

Substances：

Year:  2018        PMID： 30323049      PMCID： PMC6325227          DOI： 10.1128/AAC.01665-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.

Authors:  Prachi K Dandekar; Dana Maglio; Christina A Sutherland; Charles H Nightingale; David P Nicolau
Journal:  Pharmacotherapy       Date:  2003-08       Impact factor: 4.705

2.  Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).

Authors:  A C Gales; R N Jones; K R Forward; J Liñares; H S Sader; J Verhoef
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

3.  Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.

Authors:  Amabel Lapuebla; Marie Abdallah; Olawole Olafisoye; Christopher Cortes; Carl Urban; John Quale; David Landman
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

4.  Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.

Authors:  Scott J Hecker; K Raja Reddy; Maxim Totrov; Gavin C Hirst; Olga Lomovskaya; David C Griffith; Paula King; Ruslan Tsivkovski; Dongxu Sun; Mojgan Sabet; Ziad Tarazi; Matthew C Clifton; Kateri Atkins; Amy Raymond; Kristy T Potts; Jan Abendroth; Serge H Boyer; Jeffrey S Loutit; Elizabeth E Morgan; Stephanie Durso; Michael N Dudley
Journal:  J Med Chem       Date:  2015-03-17       Impact factor: 7.446

Review 5.  β-Lactamase inhibitors: what you really need to know.

Authors:  Paul G Ambrose; Olga Lomovskaya; David C Griffith; Michael N Dudley; Brian VanScoy
Journal:  Curr Opin Pharmacol       Date:  2017-10-27       Impact factor: 5.547

6.  Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.

Authors:  Christopher M Rubino; Sujata M Bhavnani; Jeffery S Loutit; Elizabeth E Morgan; Dan White; Michael N Dudley; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

7.  Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.

Authors:  William J Weiss; Mark E Pulse; Phung Nguyen; Kelly Peterson; Jessica Silva; Jerry W Simecka; David Valtierra; Mojgan Sabet; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 8.  Pharmacokinetic and pharmacodynamic properties of meropenem.

Authors:  David P Nicolau
Journal:  Clin Infect Dis       Date:  2008-09-15       Impact factor: 9.079

9.  Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.

Authors:  Mojgan Sabet; Ziad Tarazi; Thomas Nolan; Jonathan Parkinson; Debora Rubio-Aparicio; Olga Lomovskaya; Michael N Dudley; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191
  9 in total
  6 in total

1.  Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative.

Authors:  Christian M Gill; Tomefa E Asempa; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

Review 2.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

Review 3.  New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review.

Authors:  Angela Raffaella Losito; Francesca Raffaelli; Paola Del Giacomo; Mario Tumbarello
Journal:  Antibiotics (Basel)       Date:  2022-04-26

Review 4.  The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.

Authors:  Krisztina M Papp-Wallace
Journal:  Expert Opin Pharmacother       Date:  2019-09-09       Impact factor: 3.889

5.  Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections.

Authors:  Chih-Cheng Lai; Chi-Chung Chen; Hung-Jen Tang
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

Review 6.  The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections.

Authors:  Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.